1 |
Supersaxo, A., Hein, W.R., Steffen, H., 1990. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 7, 167-169.
DOI
|
2 |
Oussoren, C., Zuidema, J., Crommelin, D.J., Storm, G., 1997. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose. Biochim Biophys Acta 1328, 261-272.
DOI
|
3 |
Paliwal, R., Paliwal, S. R., Mishra, N., Mehta, A., Vyas, S.P., 2009. Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate. Int J Pharm 380, 181-188.
DOI
|
4 |
Parker, R. J., Hartman, K.D., Sieber, S.M., 1981. Lymphatic absorption and tissue disposition of liposome-entrapped [14C]adriamycin following intraperitoneal administration to rats. Cancer Res 41, 1311-1317.
|
5 |
Patel, H.M., Boodle, K.M., Vaughan-Jones, R., 1984. Assessment of the potential uses of liposomes for lymphoscintigraphy and lymphatic drug delivery. Failure of 99m-technetium marker to represent intact liposomes in lymph nodes. Biochim Biophys Acta 801, 76-86.
DOI
ScienceOn
|
6 |
Pepper, M.S., Skobe, M., 2003. Lymphatic endothelium: morphological, molecular and functional properties. J Cell Biol 163, 209-213.
DOI
|
7 |
Rao, D.A., Forrest, M.L., Alani, A.W., Kwon, G.S., Robinson, J. R., 2010. Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery. J Pharm Sci 99, 2018-2031.
DOI
|
8 |
Senior, J.H., 1987. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 3, 123-193.
|
9 |
Shin, S.B., Cho, H.Y., Kim, D.D., Choi, H.G., Lee, Y.B., 2010. Preparation and evaluation of tacrolimus-loaded nanoparticles for lymphatic delivery. Eur J Pharm Biopharm 74, 164-171.
DOI
|
10 |
Singh, R., Lillard, J.W., Jr., 2009. Nanoparticle-based targeted drug delivery. Exp Mol Pathol 86, 215-223.
DOI
|
11 |
Allen, T., Hansen, C., Guo, L., 1993. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochimica et Biophysica Acta (BBA)-Biomembranes 1150, 9-16.
DOI
|
12 |
Allen, T., Moase, E., 1996. Therapeutic opportunities for targeted liposomal drug delivery. Advanced drug delivery reviews 21, 117-133.
DOI
|
13 |
Cavanagh, L.L., Von Andrian, U.H., 2002. Travellers in many guises: the origins and destinations of dendritic cells. Immunol Cell Biol 80, 448-462.
DOI
|
14 |
Chambers, A.F., Groom, A.C., Macdonald, I.C., 2002. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2, 563-572.
DOI
|
15 |
Swartz, M.A., 2001. The physiology of the lymphatic system. Adv Drug Deliv Rev 50, 3-20.
DOI
|
16 |
Takakura, Y., Atsumi, R., Hashida, M., Sezaki, H., 1987. Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. II. Disposition and pharmacokinetics following intravenous and intramuscular administration. International Journal of Pharmaceutics 37, 145-154.
DOI
|
17 |
Takakura, Y., Matsumoto, S., Hashida, M., Sezaki, H., 1984. Enhanced lymphatic delivery of mitomycin C conjugated with dextran. Cancer Res 44, 2505-2510.
|
18 |
Tanis, P.J., Nieweg, O.E., Valdes Olmos, R.A., Kroon, B.B., 2001. Anatomy and physiology of lymphatic drainage of the breast from the perspective of sentinel node biopsy. J Am Coll Surg 192, 399-409.
DOI
|
19 |
Trevaskis, N.L., Charman, W.N., Porter, C.J., 2008. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev 60, 702-716.
DOI
|
20 |
Trevaskis, N.L., Porter, C.J., Charman, W.N., 2006. The lymph lipid precursor pool is a key determinant of intestinal lymphatic drug transport. J Pharmacol Exp Ther 316, 881-891.
|
21 |
Tumer, A., Kirby, C., Senior, J., Gregoriadis, G., 1983. Fate of cholesterol-rich liposomes after subcutaneous injection into rats. Biochim Biophys Acta 760, 119-125.
DOI
ScienceOn
|
22 |
Xie, Y., Bagby, T.R., Cohen, M.S., Forrest, M.L., 2009. Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies. Expert Opin Drug Deliv 6, 785-792.
DOI
|
23 |
Oussoren, C., Storm, G., 2001. Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev 50, 143-156.
DOI
|
24 |
Kohli, K., Chopra, S., Dhar, D., Arora, S., Khar, R.K., 2010. Selfemulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discov Today
|
25 |
Karajgi, J.S., Vyas, S.P., 1994. A lymphotropic colloidal carrier system for diethylcarbamazine: preparation and performance evaluation. J Microencapsul 11, 539-545.
DOI
|
26 |
Kaur, C.D., Nahar, M., Jain, N.K., 2008. Lymphatic targeting of zidovudine using surface-engineered liposomes. J Drug Target 16, 798-805.
DOI
|
27 |
Kim, C.K., Han, J.H., 1995. Lymphatic delivery and pharmacokinetics of methotrexate after intramuscular injection of differently charged liposome-entrapped methotrexate to rats. J Microencapsul 12, 437-446.
DOI
|
28 |
Ling, S.S., Magosso, E., Khan, N.A., Yuen, K.H., Barker, S.A., 2006. Enhanced oral bioavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes. Drug Dev Ind Pharm 32, 335-345.
DOI
|
29 |
Luo, G., Yu, X., Jin, C., Yang, F., Fu, D., Long, J., Xu, J., Zhan, C., and Lu, W., 2010. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int J Pharm 385, 150-156.
DOI
|
30 |
Muller, C.D., Schuber, F., 1989. Neo-mannosylated liposomes: synthesis and interaction with mouse Kupffer cells and resident peritoneal macrophages. Biochim Biophys Acta 986, 97-105.
DOI
|
31 |
Nankervis, R., Davis, S., Day, N., Shaw, P., 1996. Intestinal lymphatic transport of three retinoids in the rat after oral administration: effect of lipophilicity and lipid vehicle. International Journal of Pharmaceutics 130, 57-64.
DOI
|
32 |
O'driscoll, C.M., 2002. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci 15, 405-415.
DOI
|
33 |
Garg, M., Jain, N.K., 2006. Reduced hematopoietic toxicity, enhanced cellular uptake and altered pharmacokinetics of azidothymidine loaded galactosylated liposomes. J Drug Target 14, 1-11.
DOI
|
34 |
Charman, W., Porter, C., 1996. Lipophilic prodrugs designed for intestinal lymphatic transport. Advanced drug delivery reviews 19, 149-169.
DOI
|
35 |
Charman, W., Stella, V., 1986. Effects of lipid class and lipid vehicle volume on the intestinal lymphatic transport of DDT. International Journal of Pharmaceutics 33, 165-172.
DOI
|
36 |
Feng, L., Zhang, L., Liu, M., Yan, Z., Wang, C., Gu, B., Liu, Y., Wei, G., Zhong, G., Lu, W., 2010. Roles of dextrans on improving lymphatic drainage for liposomal drug delivery system. J Drug Target 18, 168-178.
DOI
|
37 |
Gershkovich, P., Hoffman, A., 2005. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur J Pharm Sci 26, 394-404.
DOI
|
38 |
Gursoy, R.N., Benita, S., 2004. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 58, 173-182.
DOI
|
39 |
Hawley, A.E., Illum, L., Davis, S.S., 1997. Preparation of biodegradable, surface engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake. Pharm Res 14, 657-661.
DOI
|
40 |
Immordino, M.L., Dosio, F., Cattel, L., 2006. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1, 297-315.
DOI
|
41 |
Jurisic, G., Detmar, M., 2009. Lymphatic endothelium in health and disease. Cell Tissue Res 335, 97-108.
DOI
|